Duromine is a trademark of weight loss drug – Phentermine. For about 25 years, Duromine (Phentermine) drug is sold in Australia, New Zealand and other Asia-Pacific countries. For many years, Duromine drug was sold in the UK, but was withdrawn from the British pharmaceutical market in the early 2000s. The supplier of Duromine in the UK was 3M Pharmaceuticals company. Today, 3M is the part of pharmaceutical company – iNova. Exactly, iNova is the manufacturer and exclusive distributor of Duromine drug in 2014. iNova manufactures Duromine weight loss capsules containing 15mg, 30mg and 40mg of active substance Phentermine. Duromine capsules of different strengths have different colors and markings. Color of Duromine 15mg caps: grey and green (Duromine 15*) Color of Duromine 30mg caps: grey-reddish brown (Duromine 30*) Color of Duromine 40mg caps: grey-orange (Duromine 40*) * marking on the capsule FASTER & EASIER THAN EVER BEFORE! If you want to buy Duromine capsules at low price, you can order them on online pharmacy.

Please, pay your attention to that Australia is one of the few countries wherein Duromine 40mg capsules are sold. 2 Bedroom House For Sale In Hayes MiddlesexIn many other countries (including NZ), only Duromine 15 and 30mg capsules are available for sale.Puppies For Sale Oshawa Before buying Duromine online, make sure that this weight loss drug can be delivered to the region you live. Toilet Bowl Illuminating DeviceIf you decide to buy Duromine drug online but have never taken drugs containing Phentermine, please, get to know the key information about Duromine. Phentermine (the active ingredient of Duromine) is a psychostimulant affecting mainly noradrenergic, dopaminergic, and partly serotonergic nervous systems.

By stimulating the CNS, Phentermine provides a fast, powerful and prolonged anorexigenic effect. Just 30-60 minutes after Phentermine oral intake, a person stops experiencing hunger. When taking large doses of Phentermine, the duration of anorexigenic effect may reach 24 hours. Results of long-term clinical trials have shown that Duromine helps to achieve a significant weight loss even in severe obesity. After studying the results of clinical trials, Therapeutic Goods Administration (TGA) has concluded that the benefits of Duromine exceed its potential risks. After Duromine was included in Australian Register of Therapeutic Goods (ARTG), iNova has received a license for its sale in Australia. Thus, overweight and obese Australians from 12 years and older have been prescribed Duromine. Duromine (Phentermine) stimulates the CNS, therefore can cause euphoria, anxiety, dizziness, drug dependence. Duromine provides cardiovascular effects and may cause Primary Pulmonary Hypertension (PPH), Valvular Heart Disease (VHD).

Because of potential risks, Duromine capsules should not be prescribed to pre-obese and obese patients with a history of cardiovascular diseases, cerebrovascular diseases, mental illnesses, alcoholism, and (or) drug addiction. Adolescents from 12 years and older should take a Duromine 15mg capsule once daily. Patients of mature age should take a Duromine 30mg capsule once daily. Elderly patients from 65 years (inclusive) and older should not take Duromine. The maximum daily dose of Duromine 40mg is prescribed in individual cases. Regardless of prescribed daily dose, Duromine capsules should be taken in the morning at the same time. If you miss a dose, Duromine capsule can be taken in the daytime but no less than 8 hours before bedtime. Duromine drug may cause difficulty falling asleep and insomnia, so refrain from its use in the afternoon. If a single dose of Duromine 30mg causes severe side effects, it can be divided into two intakes (A Duromine 15mg cap in the morning and a Duromine 15mg cap in the daytime).

Duromine is not the only weight loss drug containing anorexigenic agent Phentermine. Dozens of Duromine analogs (generic drugs) sold under different trademarks are available for sale at the international market. If you want to buy Duromine generic, it is quite possible that in your country it is sold under the trademarks: Acxion, Adipex, Adipex Retard, Adipex-P, Ionamin, Metermine, Redusa, Suprenza, Teramine, Terfamex, Zantryl.The woman sat on my exam table and pointed to her snug paper gown. “Doctor,” she said, “I need your help losing weight.” I spent the next several minutes speaking with her about diet and exercise, the health risks of obesity, and the benefits of weight loss—a talk I’ve been having with my patients for more than twenty years. But, like the majority of Americans, most of my patients remain overweight. Afterward, I realized that what my patient wanted was a pill that would make her lose weight. I could have prescribed her one of four drugs currently approved by the F.D.A.: two, phentermine and orlistat, that have been around for more than a decade, and two others, Belviq (lorcaserin) and Qsymia (a combination of phentermine and topiramate), that have recently come onto the market and are the first ever approved for long-term use.

(Ian Parker wrote about the F.D.A.’s approval process for new medications in this week’s issue.) The drugs work by suppressing appetite, by increasing metabolism, and by other mechanisms that are not yet fully understood. These new drugs, along with beloranib—which produces more dramatic weight loss than anything currently available but is still undergoing clinical trials—were discussed with great excitement last month by experts and researchers at the international Obesity Week conference in Atlanta. But I’ve never prescribed diet drugs, and few doctors in my primary-care practice have, either. Donna Ryan, an obesity specialist at the Pennington Biomedical Research Center at Louisiana State University, has found that only a small percentage of the doctors she has surveyed regularly prescribe any of the drugs currently approved by the F.D.A. Sales figures indicate that physicians haven’t embraced the new medications, Qsymia and Belviq, either. The inauspicious history of diet drugs no doubt contributes to doctors’ reluctance to prescribe them.

In the nineteen-forties, when doctors began prescribing amphetamines for weight loss, rates of addiction soared. Then, in the nineties, fen-phen, a popular combination of fenfluramine and phentermine, was pulled from the market when patients developed serious heart defects. Current medications are much safer, but they produce only modest weight loss, in the range of about five to ten per cent, and they do have side effects. Still, as Ryan pointed out, doctors aren’t always shy about prescribing medications that cause side effects and yield undramatic results. A five to ten per cent weight loss might not thrill patients, or even nudge them out of being overweight or obese, but it can improve diabetes control, blood pressure, cholesterol, sleep apnea, and other complications of obesity. And, although the drugs aren’t covered by Medicare or most states’ Medicaid programs, private insurance coverage of weight-loss drugs has improved and is likely to expand further under the Affordable Care Act, which requires insurers to pay for obesity treatment.

So what prevents physicians from prescribing these drugs? Several leading experts and researchers attending Obesity Week told me that the problem is that, while specialists who study obesity view it as a chronic but treatable disease, primary-care physicians are not fully convinced that they should be treating obesity at all. Even though physicians since Hippocrates have known that excess body fat can cause diseases, the American Medical Association announced that it would recognize obesity itself as a disease only a few months ago. These divergent views on obesity represent one of the widest gulfs of understanding between generalists and specialists in all of medicine. Lee M. Kaplan, co-director of the Weight Center at Massachusetts General Hospital, thinks that some bias comes from the average physician’s lack of appreciation for the complex physiology of weight homeostasis. Humans have evolved to avoid starvation rather than obesity, and we defend our body mass through an elaborate system involving the brain, the gut, fat cells, and a network of hormones and neurotransmitters, only a fraction of which have been identified.

Obesity, Kaplan said, which represents dysfunction of this system, is likely not one disease but dozens. That one person’s obesity is not like another’s may explain why some people lose a lot of weight with surgery, or a particular diet or drug, and some don’t. Kaplan thinks that if more doctors understood this, they’d view obesity treatment more receptively and realistically. He said, “If I were to say to you, ‘I have this drug that treats cancer,’ and you asked me, ‘What kind of cancer?,’ and I said, ‘All cancers,’ you’d laugh, because you recognize intuitively that cancer is a heterogeneous group of disorders. We’re going to look back on obesity one day and say the same thing.” Obesity is potentially, in part, a neurological disease. Jeffrey Flier, an endocrinologist and dean of Harvard Medical School, has shown, like others, that repeatedly eating more calories than you burn can damage the hypothalamus, an area of the brain involved in eating and satiety.

In other words, Big Gulps, Cinnabons, and Whoppers have altered our brains such that many people—particularly those with a genetic predisposition to obesity—find fattening foods all but impossible to resist once they’ve eaten enough of them. Louis J. Aronne, director of the Comprehensive Weight Control Program at New York-Presbyterian/Weill Cornell Medical Center, explained to me, “With so much calorie-dense food available, the hypothalamic neurons get overloaded and the brain can’t tell how much body fat is already stored. The response is to try to store more fat. So there’s very strong scientific evidence that obesity is not about people lacking willpower.” But this message has not found its way into society, where obese people are still often considered self-indulgent and lazy, and face widespread discrimination. Several obesity experts told me they’ve encountered doctors who confide that they just didn’t like fat people and don’t enjoy taking care of them. Even doctors who treat obese patients feel stigmatized: “diet doctor” is not a flattering term.

Donna Ryan, who switched from oncology to obesity medicine many years ago, recalls her colleagues’ surprise. “I had respect,” she says. “I was treating leukemia!” George Bray, also of the Pennington Biomedical Research Center, thinks that socioeconomic factors play into physicians’ lack of enthusiasm for treating obesity. Bray points to the work of Adam Drewnowski at the University of Washington, who has shown that obesity is, disproportionately, a disease of poverty. Because of this association, many erroneously see obesity as more of a social condition than a medical one, a condition that simply requires people to try harder. Bray said, “If you believe that obesity would be cured if people just pushed themselves away from the table, then why do you want to prescribe drugs for this non-disease, this ‘moral issue’? I think that belief permeates a lot of the medical field.” Obesity experts with whom I spoke tended to be more optimistic than other physicians about the possibility that obesity can be treated successfully and that the obesity epidemic will be curbed.

They point to exciting new research—for example, the finding that an alteration in gut bacteria, rather than mechanical shrinking of the stomach or intestine, may be what causes weight loss after gastric bypass. This raises the possibility that the benefits of surgery might become available without the surgery itself. They also note that public-health efforts seem to be reducing childhood obesity, even in poor communities. But they remain concerned that despite such promising developments, many physicians still don’t see obesity the way they do: as a serious, often preventable disease that requires intensive and lifelong treatment with a combination of diet, exercise, behavioral modification, surgery, and, potentially, drugs. Louis Aronne thinks this will change as more physicians enter the field of obesity medicine, the physiology of obesity is better understood, and more effective treatment options become available. He likens the current attitude toward obesity to the prevailing attitude toward mental illness years ago.